📡 Medscape Medical News Headlines | HIV Resistance Assay Offers Quick, Low-Cost Results for RTs
The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including dolutegravir, a first-line drug with growing resistance.
Medscape Medical News
The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including dolutegravir, a first-line drug with growing resistance.
Medscape Medical News
📡 Medscape Medical News Headlines | How Scrubs (and Time) Quietly Stole the White Coat’s Mojo
They began as plain operating-room clothes. Now scrubs are healthcare’s default uniform, a big business, and even runway inspiration. How did the white coat go out of style?
Medscape Medical News
They began as plain operating-room clothes. Now scrubs are healthcare’s default uniform, a big business, and even runway inspiration. How did the white coat go out of style?
Medscape Medical News
📡 Medscape Medical News Headlines | The Subjective Stethoscope, Diagnosing Pneumonia in Kids
Hallmark signs of pediatric pneumonia, including crackles and decreased breath sounds, shows low reliability between clinicians examining the same patients.
Medscape Medical News
Hallmark signs of pediatric pneumonia, including crackles and decreased breath sounds, shows low reliability between clinicians examining the same patients.
Medscape Medical News
📡 Medscape Headlines | Milvexian Fails to Reduce CV Events After ACS
Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Medscape Medical News
Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Medscape Medical News
📡 Medscape Headlines | Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Medscape Medical News
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Medscape Medical News
📡 Medscape Headlines | Phase 3 Eplontersen Trial Results Disappoint
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
Medscape Medical News
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
Medscape Medical News
📡 Medscape Headlines | To Anticoagulate or Not in Intermediate-Risk AF
The SINGLE-AF trial showed a small benefit for direct oral anticoagulation in patients with atrial fibrillation and one additional stroke risk factor. But the findings leave room for nuance.
theheart.org on Medscape
The SINGLE-AF trial showed a small benefit for direct oral anticoagulation in patients with atrial fibrillation and one additional stroke risk factor. But the findings leave room for nuance.
theheart.org on Medscape
📡 Medscape Medical News Headlines | Milvexian Fails to Reduce CV Events After ACS
Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Medscape Medical News
Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Medscape Medical News
📡 Medscape Medical News Headlines | Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Medscape Medical News
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Medscape Medical News
📡 Medscape Medical News Headlines | Phase 3 Eplontersen Trial Results Disappoint
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
Medscape Medical News
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
Medscape Medical News
📡 Medscape Headlines | Does AF Ablation Work?
Two sham-controlled trials seemingly showed a placebo-resistant benefit to ablation for AF, but the larger SHAM-PVI-AF trial calls those results into question.
theheart.org on Medscape
Two sham-controlled trials seemingly showed a placebo-resistant benefit to ablation for AF, but the larger SHAM-PVI-AF trial calls those results into question.
theheart.org on Medscape
📡 Medscape Headlines | Faster 1-Hour MI Rule-Out Is Safe
The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Medscape Medical News
The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Medscape Medical News
📡 Medscape Headlines | Edoxaban Falls Short After Intracranial Hemorrhage in AF
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
Medscape Medical News
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
Medscape Medical News
📡 Medscape Headlines | Drug Benefit Seen in Nonobstructive HCM
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Medscape Medical News
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Medscape Medical News
📡 Medscape Headlines | Tailored Approach Shortens Endocarditis Therapy
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
Medscape Medical News
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
Medscape Medical News
📡 Medscape Medical News Headlines | Faster 1-Hour MI Rule-Out Is Safe
The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Medscape Medical News
The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Medscape Medical News
📡 Medscape Medical News Headlines | Edoxaban Falls Short After Intracranial Hemorrhage in AF
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
Medscape Medical News
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
Medscape Medical News
📡 Medscape Medical News Headlines | Drug Benefit Seen in Nonobstructive HCM
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Medscape Medical News
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Medscape Medical News
❤1
📡 Medscape Medical News Headlines | Tailored Approach Shortens Endocarditis Therapy
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
Medscape Medical News
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
Medscape Medical News
❤1
📡 Medscape Medical News Headlines | Food Noise, Weight Stigma, and Managing Obesity
Why doesn’t food noise go quiet for everyone on GLP-1s? Why is the bias against them getting louder? And what does long-term obesity management actually look like?
Medscape Medical News
Why doesn’t food noise go quiet for everyone on GLP-1s? Why is the bias against them getting louder? And what does long-term obesity management actually look like?
Medscape Medical News
❤1